Company VBI Vaccines Inc. Toronto S.E.

Equities

VBV

CA91822J1030

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for VBI Vaccines Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 03:09:59 24/03/2018 am IST			5-day change	1st Jan Change
4.82 ^CAD	-5.12%		-7.66%	-10.58%

16/04	VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/04	North American Morning Briefing : Stock Futures -2-	DJ

VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

USD in Million	2022	Weight	2023	Weight	Delta
License 41.4 %	-	-	4	41.4 %	-
Vaccines 35.8 %	1	86.0 %	3	35.8 %	+233.73%
Research & Development Service 22.8 %	0	14.0 %	2	22.8 %	+1,210.60%

USD in Million	2022	Weight	2023	Weight	Delta
China/Hong Kong 64.3 %	0	6.1 %	6	64.3 %	+8,362.12%
United States 21.3 %	1	64.2 %	2	21.3 %	+165.47%
Europe 12.5 %	0	0.6 %	1	12.5 %	+17,983.33%
Israel 1.9 %	0	29.1 %	0	1.9 %	-46.98%

Managers	Title	Age	Since
Jeff Baxter CEO	Chief Executive Officer	62	01/16/01
Nell Beattie DFI	Director of Finance/CFO	36	09/15/09
David Anderson CTO	Chief Tech/Sci/R&D Officer	54	06/16/06
Francisco Diaz-Mitoma CTO	Chief Tech/Sci/R&D Officer	69	01/16/01
Nicole Anderson IRC	Investor Relations Contact	-	01/17/01
Athena Kartsaklis PRN	Corporate Officer/Principal	59	23/17/23
Misha Nossov PRN	Corporate Officer/Principal	-	01/10/01
John Dillman PRN	Corporate Officer/Principal	56	12/22/12
Avi Mazaltov PRN	Corporate Officer/Principal	62	30/17/30
T. Buckley PRN	Corporate Officer/Principal	48	01/01/01

Members of the board	Title	Age	Since
Vaughn Himes BRD	Director/Board Member	63	24/23/24
Steven Gillis CHM	Chairman	71	01/05/01
Jeff Baxter CEO	Chief Executive Officer	62	01/16/01
Damian Braga BRD	Director/Board Member	68	09/20/09
Michel de Wilde BRD	Director/Board Member	74	01/16/01
Blaine McKee BRD	Director/Board Member	59	11/19/11
Nell Beattie DFI	Director of Finance/CFO	36	09/15/09
Joanne Cordeiro BRD	Director/Board Member	66	15/19/15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	28,682,275	25,243,110 ( 88.01 %)	0	88.01 %

Name	Equities	%	Valuation
Perceptive Advisors LLC 4.816 %	1,381,355	4.816 %	827 432 $
Perceptive Advisors LLC 4.399 %	1,261,710	4.399 %	755 764 $
ARCH Venture Partners LLC 3.637 %	1,043,292	3.637 %	624 932 $
Alyeska Investment Group LP 2.184 %	626,436	2.184 %	375 235 $
Brii Biosciences Ltd. 1.092 %	313,265	1.092 %	187 646 $
Vanguard Group, Inc. (Subfiler) 0.6430 %	184,436	0.6430 %	110 477 $
Geode Capital Management LLC 0.4837 %	138,729	0.4837 %	83 099 $
BlackRock Institutional Trust Co. NA 0.3786 %	108,591	0.3786 %	65 046 $
Cambridge Investment Research, Inc. 0.2931 %	84,082	0.2931 %	50 365 $
Citadel Securities GP LLC 0.2526 %	72,449	0.2526 %	43 397 $

VBI Vaccines, Inc.

160 2nd Street Floor 3

02142, Cambridge

http://www.vbivaccines.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6325 USD

Average target price

5 USD

Spread / Average Target

+690.51%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+26.37%	48.16B
IQVIA HOLDINGS INC.	-1.01%	41.73B
LONZA GROUP AG	+46.00%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+9.34%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	18.96B
BIO-TECHNE CORPORATION	+6.23%	12.92B
MEDPACE HOLDINGS, INC.	+26.99%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.77B

Other Biotechnology & Medical Research